Matritech, Sysmex terminate license pact

Matritech Inc. of Newton and Sysmex Corp. said today they will terminate a 2002 agreement under which Sysmex was granted a license for a Matritech technology that can be used in screening for cervical cancer.

All rights licensed in the agreement revert to Matritech as of today, the companies said.

Last month, Matritech agreed to be acquired by Inverness Medical Innovations Inc., Waltham company first known for over-the-counter pregnancy and fertility tests, for an initial purchase price of $36 million.

Matritech develops protein-based diagnostic products for the early detection of cancer.

Sysmex is a global company headquartered in Japan.
(By Chris Reidy, Globe staff)